Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11794365 | 0.87 | SLC2A1 (0.57) | SLC2A1PARP1MAP4K4ALDH1A1CYP2D6 | |
| SCHEMBL14433569 | 0.87 | PRMT6 (0.42) | ALDH1A1KMT2A | |
| SCHEMBL13884278 | 0.85 | ALDH1A1 (0.40) | SLC2A1PARP1ALDH1A1CA2MEN1 | |
| SCHEMBL18557169 | 0.80 | LMNA (0.36) | SLC2A1CYP2D6CASR | |
| SCHEMBL20631430 | 0.79 | SLC2A1 (0.51) | SLC2A1PARP1MAP4K4ALDH1A1CYP2D6 | |
| SCHEMBL27112902 | 0.79 | TP53 (0.39) | ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL14229981 | 0.79 | SLC2A1 (0.51) | SLC2A1PARP1MAP4K4ALDH1A1CYP2D6 | |
| SCHEMBL22404403 | 0.79 | SLC2A1 (0.34) | SLC2A1 | |
| SCHEMBL13208280 | 0.79 | BCHE (0.47) | SLC2A1PARP1MAP4K4ALDH1A1CYP2D6 | |
| SCHEMBL18067758 | 0.79 | TP53BP1 (0.47) | ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | SLC2A1 2452/4885PARP1 619/4885MAP4K4 3846/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | SLC2A1 2452/4885PARP1 619/4885MAP4K4 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.